NF-κB’s importance stems from its dual identity. In healthy tissue, it is an indispensable guardian. The pathway exists in five family members—NF-κB1 (p50/p105), NF-κB2 (p52/p100), RelA (p65), RelB, and c-Rel—that pair into homo- and heterodimers. Under resting conditions, these dimers are held inactive in the cytoplasm by inhibitory IκB proteins, chiefly IκBα. When the cell encounters pro-inflammatory cytokines such as TNF-α or IL-1β, or pathogen-associated molecular patterns recognized by toll-like receptors, the canonical pathway springs into action. Receptor engagement recruits adaptor proteins like TRADD and MyD88, which activate the IκB kinase (IKK) complex, composed of IKKα, IKKβ, and the regulatory subunit NEMO. IKK phosphorylates two conserved serine residues on IκBα, tagging it for ubiquitination and proteasomal destruction. Freed from its inhibitor, the p65/p50 heterodimer translocates to the nucleus, binds κB DNA sequences through its Rel homology domain, and switches on genes governing inflammation, immunity, cell survival, and proliferation. A parallel non-canonical route, driven by NF-κB-inducing kinase and IKKα, processes the precursor p100 into p52, forming p52/RelB dimers that regulate B cell maturation and lymphoid organogenesis. Both arms are essential, but both can be hijacked.

The trouble begins when this exquisitely regulated system never switches off. Persistent NF-κB activation is now recognized as a defining feature of chronic low-grade inflammation, the smoldering substrate on which cancers, cardiovascular disease, metabolic syndrome, and neurodegenerative conditions take root. In tumorigenesis, constitutive NF-κB signaling acts as a multipurpose engine of malignancy. It suppresses apoptosis by upregulating anti-death proteins such as Bcl-2, Bcl-xL, survivin, and the inhibitor-of-apoptosis proteins, allowing damaged cells to evade programmed cell death. It fuels angiogenesis through vascular endothelial growth factor and interleukin-8, arming growing tumors with the vasculature they need to expand. It catalyzes metastasis by inducing the epithelial-to-mesenchymal transition, upregulating transcription factors like Snail and Twist while silencing E-cadherin, and by stimulating matrix metalloproteinases that degrade the extracellular matrix. Perhaps most frustrating for oncologists, NF-κB also underwrites chemoresistance, boosting drug efflux pumps such as MDR1 and BCRP and accelerating DNA repair programs involving XRCC1 and RAD51 that let cancer cells shrug off chemotherapy-induced damage.

The review’s authors catalogue this pathology across organ systems in striking detail. In breast cancer, elevated nuclear NF-κB1 expression marks a high-risk subset of estrogen receptor-positive tumors, and knockdown of NF-κB1 in inflammatory breast cancer cells impairs the motility that underlies their notorious metastatic phenotype. In gastric cancer, the bacterium Helicobacter pylori emerges as a master manipulator: its virulence factors, including the lipopolysaccharide metabolite ADP-heptose, activate NF-κB through the cytosolic receptor ALPK1 and its partner TIFA, recruiting the TRAF6–TAK1–IKK cascade and sustaining the inflammatory milieu from which malignancy arises. Genetic polymorphisms in NFKB1, NFKBIA, IKBKB, TNIP1, and MYD88 all correlate with gastric cancer risk or survival, and in mice, loss of NF-κB1 produces invasive intestinal-type gastric tumors in a STAT-1-dependent manner. In prostate cancer, NF-κB upregulates androgen receptor splice variants and amplifies cytokine loops involving IL-6, IL-8, and TNF-α that drive castration-resistant disease, while in colorectal cancer, p50 homodimers skew macrophage polarization toward a pro-tumorigenic state and cooperate with the anti-apoptotic protein BAG-1 at the promoters of EGFR and COX-2. Non-small cell lung cancer shows uniformly elevated NF-κB subunit expression, and nuclear—not cytoplasmic—RelA localization predicts worse five-year survival. Even glioblastoma multiforme, the most lethal brain tumor, depends on NF-κB, with genetic silencing of the pathway or its target Timp1 slowing progression in experimental models.

Against this formidable molecular machinery, the review positions an equally detailed arsenal drawn from the plant kingdom. The unifying logic is elegant: rather than attacking NF-κB with blunt synthetic inhibitors—which have repeatedly failed in clinical trials because of off-target toxicity stemming from the pathway’s many legitimate functions—phytochemicals exploit multiple low-intensity intervention points across the cascade. Curcumin, the diarylheptanoid from turmeric, suppresses IKK activity and prevents IκBα phosphorylation, trapping NF-κB in the cytoplasm and reducing the transcription of pro-inflammatory and pro-survival genes. Resveratrol, the stilbene from grapes and red wine, targets NEMO and IKK to block the ubiquitin-dependent steps that the pathway requires, while also diminishing NF-κB’s DNA-binding capacity. Epigallocatechin gallate, the principal catechin of green tea, prevents lipopolysaccharide-induced IκBα degradation and blocks the nuclear migration of RelA, engaging ROS-sensitive signaling routes that frequently converge on NF-κB activation.

The pharmacological nuances the authors document reveal how structurally diverse compounds converge on the same pathway through distinct molecular tactics. Quercetin, a flavonoid abundant in onions and apples, inhibits NF-κB DNA-binding activity and induces dephosphorylation and upregulation of IκBα, showing half-maximal inhibitory concentrations of 20 to 35 micromolar against colon cancer cell lines, and suppresses IKKα expression in non-small cell lung cancer cells. Apigenin, from chamomile, binds IKK directly—an action the review notes outperformed conventional IKK inhibitors in prostate cancer cells, producing cell-cycle arrest—and simultaneously curtails COX-2 expression and pro-inflammatory cytokine biosynthesis. Genistein, the soy isoflavone, downregulates NF-κB production and its transcriptional activity across breast, ovarian, liver, colon, and cervical cancer models. Gingerol blocks TPA-induced phosphorylation of p65; gallic acid limits the pathway by lowering acetylation of RelA; pterostilbene, a more bioavailable analog of resveratrol from blueberries, suppresses upstream PI3K/Akt and PKC signaling that would otherwise activate both NF-κB and AP-1, preventing epithelial-to-mesenchymal transition and MMP-9-driven invasion. Salidroside from Rhodiola rosea couples IκBα-stabilizing effects with activation of the antioxidant Nrf2 pathway, while the lignan honokiol from Magnolia bark adds the rare ability to cross the blood–brain barrier. Silymarin’s flavonolignans disrupt NF-κB–DNA crosstalk, and carnosol from rosemary and sage inhibits IκBα kinase activity while also damping MAPK pathways that feed NF-κB expression.

Beyond the classical dietary polyphenols, the review extends its mechanistic map to non-dietary phytochemicals that corroborate the same principles. The naphthoquinone plumbagin induces apoptosis while inhibiting NF-κB through redox cycling and reactive oxygen species generation. The iridoid glycosides aucubin and catalpol prevent IκBα degradation and p65 nuclear translocation, with catalpol additionally blocking TGF-β1-driven epithelial-to-mesenchymal transition in lung cancer cells via Smad2/3 suppression. Sesquiterpene lactones display perhaps the most direct mechanism of all: helenalin from Arnica covalently alkylates a cysteine in the p65 Rel homology domain, physically obstructing DNA binding, while parthenolide from feverfew blocks p65 nucleocytoplasmic transport and enhances cyclophosphamide’s efficacy in lung cancer models. Terpenes limonene and α-pinene prevent the phosphorylation cascades that release NF-κB from its cytoplasmic custody, triterpenes such as lupeol, betulin, and ginsenosides stabilize IκBα and restrain IKK activity, and carotenoids like lycopene and β-carotene inhibit IκB phosphorylation in prostate and other cancer models.

Yet the authors are refreshingly candid about the gulf between laboratory promise and clinical reality. Most of these compounds display potent effects in vitro and in animal models at concentrations that human pharmacokinetics struggle to replicate. Curcumin’s poor aqueous solubility and rapid metabolism have limited its clinical translation despite decades of enthusiasm; resveratrol’s bioavailability is notoriously low; quercetin’s early-phase trials confirmed safety but produced equivocal therapeutic signals; and EGCG’s phase I trial in lung cancer radiotherapy showed tolerability but no significant impact on tumor progression. Artemisinin illustrates a different constraint: while antimalarial doses sit in the nanomolar range, the micromolar concentrations needed for anticancer effects risk neurotoxicity. The review identifies poor solubility, limited cellular penetration, off-target effects, and dose-dependent toxicity as the principal barriers separating bench from bedside.

The path forward, the authors argue, lies in delivery innovation and combination strategies. Nanotechnology—liposomal formulations, microencapsulation, and nano-emulsions—can dramatically enhance solubility, stability, and target specificity while reducing the doses required for efficacy, and nano-phytochemical formulations have already demonstrated superior performance over free compounds in multiple cancer models. Because NF-κB sits at the confluence of PI3K/Akt, MAPK, and p53 signaling, polyphenols’ capacity to modulate these intersecting networks simultaneously may prove most valuable as adjuvants that sensitize tumors to conventional chemotherapy and targeted therapy, echoing curcumin’s demonstrated ability to potentiate gemcitabine in pancreatic cancer and genistein’s sensitization of cervical cancer cells to cisplatin.

What makes this synthesis genuinely newsworthy is its reframing of a familiar message. The advice to eat fruits, vegetables, tea, and spices is hardly revolutionary, but grounding it in a precise, multi-point mechanistic map of NF-κB regulation transforms dietary polyphenols from vague antioxidants into a coherent pharmacological concept. Inflammation-driven cancer is a problem of a transcription factor that will not rest, and the review makes a compelling case that the plant world supplies molecules calibrated, over millions of years of co-evolution, to modulate exactly the checkpoints—IKK phosphorylation, IκBα degradation, p65 translocation, DNA binding, and RelA acetylation—whose dysregulation defines the disease. The challenge now is to convert that molecular insight into formulations and trials robust enough for the clinic.

Severe acute pancreatitis, characterized by sudden and intense inflammation of the pancreas, commonly triggers a cascade of local and systemic immune responses that exacerbate tissue injury and precipitate multi-organ failure. Despite advances in critical care, targeted therapies remain elusive, primarily due to incomplete knowledge of the molecular mechanisms governing inflammation in this context. Annexin A1, a calcium-dependent phospholipid-binding protein, has emerged as a promising endogenous mediator known for its anti-inflammatory properties in various tissues, yet its precise involvement in SAP had remained poorly defined.

The study meticulously delineates how Annexin A1 orchestrates the inflammatory milieu through its interactions with components of the innate immune system. Using sophisticated animal models that replicate severe acute pancreatitis, researchers observed that deficiency in Annexin A1 correlates with heightened inflammatory cell infiltration, amplified cytokine networks, and exacerbated tissue necrosis in both pancreatic and extra-pancreatic organs. Conversely, augmented expression of Annexin A1 corresponded with a marked reduction in inflammatory markers and preservation of tissue integrity, underscoring its protective role.

At the cellular level, Annexin A1 appears to exert its effects by modulating neutrophil activity and macrophage polarization. Neutrophils, which are frontline responders in acute inflammatory events, can induce collateral damage through the release of proteolytic enzymes and reactive oxygen species. Annexin A1 was found to inhibit excessive neutrophil recruitment and activation, thereby curtailing the harmful inflammatory overdrive. Simultaneously, it favored the polarization of macrophages toward a reparative phenotype, promoting resolution of inflammation and tissue healing.

Mechanistically, Annexin A1’s interaction with formyl peptide receptors (FPRs) plays a pivotal role in signaling pathways that temper pro-inflammatory responses. By binding to these G-protein coupled receptors, Annexin A1 triggers intracellular cascades that downregulate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a master transcription factor driving the expression of multiple pro-inflammatory genes. This inhibitory effect on NF-κB attenuates cytokine storms, a hallmark of severe pancreatitis-associated systemic inflammation. The elucidation of this receptor-mediated mechanism empowers researchers to envision pharmacological mimetics of Annexin A1 as next-generation anti-inflammatory agents.

Importantly, systemic inflammation during SAP is known to induce damage in organs beyond the pancreas, such as the lungs, kidneys, and liver, contributing to the syndrome’s lethality. The researchers demonstrated that enhancing Annexin A1 expression not only mitigated local pancreatic injury but also significantly reduced extra-pancreatic organ damage. This systemic protective effect underscores the protein’s potential as a holistic therapeutic target, capable of modulating the immune landscape both at the primary site of injury and throughout the body’s inflammatory network.

The study’s findings carry substantial translational value. In clinical scenarios, early intervention to boost Annexin A1 activity could arrest the progression of SAP’s destructive immunopathology before irreversible organ failure ensues. Current treatments largely focus on supportive care, leaving an unmet need for disease-modifying therapies. The molecular insights presented offer a foundational framework for developing biologics or small molecules that amplify Annexin A1’s function or mimic its activity, setting a novel paradigm in SAP management.

Further investigations into the temporal dynamics of Annexin A1 expression during pancreatitis revealed that its upregulation coincides with early inflammatory stages, suggesting a natural compensatory mechanism that attempts to restore immunological homeostasis. However, this endogenous response may be insufficient in severe cases, warranting therapeutic augmentation. These data support the concept of Annexin A1 as a biomarker for disease severity and a predictive tool for clinical outcomes, enhancing diagnostic precision.

Advanced imaging techniques and immunohistochemical analyses confirmed that Annexin A1 localizes predominantly to areas with massive inflammatory infiltrates, implicating it actively in modulating cellular crosstalk within inflamed tissues. This spatial association informs the design of targeted drug delivery systems that concentrate therapeutic agents in inflamed pancreatic microenvironments, maximizing efficacy while minimizing off-target effects.

The study also touches upon the interplay between Annexin A1 and the adaptive immune system. While acute pancreatitis is largely driven by innate immune mechanisms, the role of T cells and other adaptive components is increasingly recognized. Annexin A1 was observed to influence T cell responses indirectly by shaping antigen-presenting cell phenotypes, thereby orchestrating a balanced immune repertoire that prevents chronic inflammation and fibrosis—common complications following SAP resolution.

In addition to immune modulation, Annexin A1’s involvement in cellular apoptosis and autophagy pathways was explored. These processes are vital for removing damaged pancreatic acinar cells and limiting inflammatory stimuli. By facilitating controlled cell death and clearance, Annexin A1 contributes to tissue homeostasis and recovery, highlighting its multifaceted role beyond simple inflammation suppression.

The researchers emphasize the necessity of future clinical trials to validate these preclinical findings and to assess the safety and efficacy of Annexin A1-based therapies in human populations. Such trials would need to stratify patients based on severity and incorporate biomarkers reflecting Annexin A1 activity to tailor personalized treatment regimens effectively.

Collectively, this comprehensive investigation redefines our understanding of severe acute pancreatitis by positioning Annexin A1 as a master regulator of inflammation and tissue preservation. These novel insights unlock new therapeutic avenues, offering hope to millions affected by a disease that has long challenged clinicians due to its unpredictable course and limited treatment options. As research progresses, Annexin A1-targeted interventions may revolutionize the clinical management of SAP, ushering in an era of precision medicine in inflammatory pancreatic disorders.

The convergence of molecular biology, immunology, and clinical science in this study exemplifies the power of interdisciplinary approaches to unravel complex disease mechanisms. It also underscores the importance of endogenous regulatory proteins like Annexin A1 in maintaining immune balance and preventing destructive inflammation—principles that could extend to other acute inflammatory diseases beyond pancreatitis. This research not only enhances our conceptual framework but also ignites a new wave of therapeutic innovation poised to save lives.

Subject of Research:
Severe acute pancreatitis and the regulatory role of Annexin A1 in inflammation and immune response.

Article Title:
Correction: Annexin A1 regulates inflammatory-immune response and reduces pancreatic and extra-pancreatic injury during severe acute pancreatitis.

Article References:
Lin, S., Liang, F., Chen, C. et al. Correction: Annexin A1 regulates inflammatory-immune response and reduces pancreatic and extra-pancreatic injury during severe acute pancreatitis. Genes Immun (2025). https://doi.org/10.1038/s41435-025-00348-0

Image Credits:
AI Generated